EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations

EyePoint, Inc.

Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.
Full-year net loss $130.9M ($2.32/share) vs $70.8M loss prior year; revenue $43.3M vs $46.0M.
DURAVYU Phase 3 wet AMD trials LUGANO (>50% enrolled) and LUCIA on track; enrollment completion H2 2025, topline data 2026.
Phase 2 VERONA DME trial met endpoints: BCVA +10.3 letters vs +3.0 control; 43% had absence of DME.
Cash $371M as of Dec 31, 2024; runway into 2027; no equity capital plans for 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.